-
1 Comment
Parenteral Drugs (India) Limited is currently in a long term uptrend where the price is trading 40.8% above its 200 day moving average.
From a valuation standpoint, the stock is 81.2% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.9.
Parenteral Drugs (India) Limited's total revenue sank by 71.9% to $20M since the same quarter in the previous year.
Its net income has dropped by 18.5% to $-310M since the same quarter in the previous year.
Finally, its free cash flow grew by 14.4% to $608M since the same quarter in the previous year.
Based on the above factors, Parenteral Drugs (India) Limited gets an overall score of 3/5.
| Exchange | NSE |
|---|---|
| CurrencyCode | INR |
| ISIN | INE904D01019 |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| PE Ratio | None |
|---|---|
| Target Price | None |
| Beta | 0.16 |
| Market Cap | 101M |
| Dividend Yield | None |
Parenteral Drugs (India) Limited operates as a healthcare company in India. The company manufactures pharmaceutical products, including intravenous infusion, inhalation, veterinary infusion, etc. It also offers IV fluids, such as carbohydrates and electrolytes, diuretics, dialysis and irrigation solutions, anti-infective and anti-fungal products, and others; and oncology and anaesthesia products. The company also exports its products to Iraq, Yemen, Mozambique, Ghana, Kenya, Kyrgyzstan, Uzbekistan, Sudan, Vietnam, Cambodia, Liberia, Sri Lanka, Nepal, Myanmar, and Cameroon. The company was incorporated in 1983 and is based in Indore, India.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for PDPL.NSE using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
